D
Skye Bioscience, Inc. SKYE
$1.82 $0.031.68% NASDAQ
Recommendation
Prev Close
$1.82
Volume
54
Avg Vol (90D)
523,510
Market Cap
$56.37M
Dividend & Yield
--
52-Week Range
$1.14 - $13.51
P/E (TTM)
--
EPS (TTM)
-$0.7287
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Skye Bioscience (SKYE) Grants Stock Options to New Employee SKYE Stock News
4/27/2025 - GuruFocus
Skye Bioscience announces inducement grant under Nasdaq listing rule
4/27/2025 - TipRanks Financial Blog
Skye Bioscience announces inducement grant under Nasdaq listing rule
4/27/2025 - The Fly
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
4/26/2025 - Globe Newswire
Will Skye Bioscience (NASDAQ:SKYE) Spend Its Cash Wisely?
4/22/2025 - Simply Wall St
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)
4/21/2025 - TipRanks Financial Blog
William Blair Predicts Skye Bioscience Q2 Earnings
4/18/2025 - MarketBeat
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
4/16/2025 - SeekingAlpha
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
4/16/2025 - Seeking Alpha - Long Ideas
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
4/15/2025 - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium
4/15/2025 - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in ...
4/15/2025 - GuruFocus
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss Results in Preclinical Study ...
4/15/2025 - GuruFocus
Skye Bioscience announces new preclinical data for nimacimab
4/15/2025 - The Fly
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in ...
4/15/2025 - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
4/15/2025 - Globe Newswire
Skye Bioscience to Conduct Meetings at Piper Sandler Conference SKYE Stock News
4/14/2025 - GuruFocus
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
4/14/2025 - GuruFocus
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
4/14/2025 - Globe Newswire
Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum
3/22/2025 - MarketBeat
Skye Bioscience's (SKYE) "Outperform" Rating Reiterated at William Blair
3/22/2025 - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript
3/22/2025 - Insider Monkey
Skye Bioscience's Positive Earnings Call Highlights Nimacimab Progress
3/22/2025 - TipRanks Financial Blog
Skye Bioscience (NASDAQ:SKYE) Releases Earnings Results, Beats Estimates By $0.06 EPS
3/21/2025 - MarketBeat
Skye Bioscience (SKYE) Gets a Buy from Scotiabank
3/21/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$29.90M
EBIT (TTM)
-$30.19M
Net Income (TTM)
-$26.57M
Balance Sheet
Total Assets (Q)
$72.76M
Total Debt (Q)
$455.60K
Total Liabilities (Q)
$4.61M
Book Value Per Share (Q)
$2.20
Cash Flow
Cash from Operations (TTM)
-$25.24M
Cash from Investing (TTM)
-$245.60K
Cash from Financing (TTM)
$83.56M
Net Change in Cash (TTM)
$58.08M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.81
7-Day Total Return
15.19%
30-Day Total Return
-27.20%
60-Day Total Return
-51.47%
90-Day Total Return
-46.15%
Year to Date Total Return
-36.14%
1-Year Total Return
-86.00%
2-Year Total Return
-47.25%
3-Year Total Return
-79.78%
5-Year Total Return
-91.53%
52-week Low
Apr 08, 2025 - $1.14
52-week High
Apr 29, 2024 - $13.51
Valuation
Market Cap
$56.37M - Micro Cap
Enterprise Value
-$11.59M
Price/Sales (TTM)
--
Price/Book (Q)
0.83
Dividends and Shares
Shares Outstanding
39.97M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
skyebioscience.com
Phone Number
858 410 0266
Address
11250 El Camino Real
San Diego, CA 92130
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed